Correlation Between Pacira BioSciences, and China Pharma

Can any of the company-specific risk be diversified away by investing in both Pacira BioSciences, and China Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Pacira BioSciences, and China Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Pacira BioSciences, and China Pharma Holdings, you can compare the effects of market volatilities on Pacira BioSciences, and China Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Pacira BioSciences, with a short position of China Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Pacira BioSciences, and China Pharma.

Diversification Opportunities for Pacira BioSciences, and China Pharma

-0.1

Correlation Coefficient

Pacira BioSciences,  China Pharma

Good diversification

The 3 months correlation between Pacira and China is -0.1. Overlapping area represents the amount of risk that can be diversified away by holding Pacira BioSciences, and China Pharma Holdings in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on China Pharma Holdings and Pacira BioSciences, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Pacira BioSciences, are associated (or correlated) with China Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of China Pharma Holdings has no effect on the direction of Pacira BioSciences, i.e., Pacira BioSciences, and China Pharma go up and down completely randomly.

Pair Corralation between Pacira BioSciences, and China Pharma

Given the investment horizon of 90 days Pacira BioSciences, is expected to generate 0.49 times more return on investment than China Pharma. However, Pacira BioSciences, is 2.05 times less risky than China Pharma. It trades about 0.26 of its potential returns per unit of risk. China Pharma Holdings is currently generating about -0.01 per unit of risk. If you would invest  1,273  in Pacira BioSciences, on September 12, 2024 and sell it today you would earn a total of  760.00  from holding Pacira BioSciences, or generate 59.7% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Pacira BioSciences,  vs.  China Pharma Holdings

Pacira BioSciences,

Risk-Adjusted Performance

20 of 100

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Pacira BioSciences, are ranked lower than 20 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady basic indicators, Pacira BioSciences, showed solid returns over the last few months and may actually be approaching a breakup point.

China Pharma Holdings

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days China Pharma Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong technical indicators, China Pharma is not utilizing all of its potentials. The latest stock price confusion, may contribute to short-horizon losses for the traders.

Pair Trading with Pacira BioSciences, and China Pharma

The main advantage of trading using opposite Pacira BioSciences, and China Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Pacira BioSciences, position performs unexpectedly, China Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in China Pharma will offset losses from the drop in China Pharma's long position.

The idea behind Pacira BioSciences, and China Pharma Holdings pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.